TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib

J Microbiol Immunol Infect. 2020 Jun;53(3):368-370. doi: 10.1016/j.jmii.2020.03.005. Epub 2020 Mar 11.

Abstract

COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles.

Keywords: COVID-19; Cytokine storm; JAK2 inhibitor; SARS-CoV-2; TH17.

MeSH terms

  • Betacoronavirus / immunology
  • COVID-19
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / pathology
  • Cytokine Release Syndrome / drug therapy*
  • Cytokines / biosynthesis
  • Cytokines / immunology
  • Humans
  • Janus Kinase 2 / antagonists & inhibitors*
  • Pandemics
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / pathology
  • Pyrrolidines / pharmacology*
  • SARS-CoV-2
  • Sulfonamides / pharmacology*
  • Th17 Cells / immunology*

Substances

  • Cytokines
  • Pyrrolidines
  • Sulfonamides
  • Fedratinib
  • JAK2 protein, human
  • Janus Kinase 2